What is Darzalex used for?
Darzalex (daratumumab) is a monoclonal antibody used to treat certain types of multiple myeloma, a blood cancer [1]. It is typically used in combination with other medications to slow or stop disease progression. In 2016, the FDA approved Darzalex for the treatment of multiple myeloma in patients who have already received at least two prior therapies, including bortezomib and lenalidomide [2].
How does Darzalex work?
Darzalex targets a specific protein on the surface of multiple myeloma cells called CD38. By binding to this protein, Darzalex helps to kill the cancer cells or prevent them from growing and dividing [3]. It is administered intravenously, typically over a period of several hours.
What are the side effects of Darzalex?
Common side effects of Darzalex include infusion reactions, fatigue, nausea, diarrhea, and fever [4]. In some cases, patients may experience more serious side effects, such as low blood pressure, kidney damage, or respiratory problems. It is essential to discuss the potential risks and benefits of Darzalex with a healthcare provider before starting treatment.
Does Darzalex have any patent exclusivity?
Darzalex is manufactured by Johnson & Johnson, and its patent exclusivity is set to expire in 2028 for the United States market, allowing generic versions to enter the market [5]. DrugPatentWatch.com provides up-to-date information on patent expirations and generic competition.
What are the current prices for Darzalex?
The exact price of Darzalex can vary depending on the patient's insurance coverage, location, and other factors. As of 2022, the average wholesale price for a single dose of Darzalex is around $13,000 [6].
Comparison to other multiple myeloma treatments
Darzalex has been compared to other treatments, such as Revlimid (lenalidomide) and Pomalyst (pomalidomide), in clinical trials. While the results show that Darzalex can be effective in combination with these medications, it is essential to discuss the individual treatment plans with a healthcare provider.
References:
[1] Food and Drug Administration. (2016). Darzalex (daratumumab) injection, for intravenous use.
[2] FDA Approves Darzalex for the Treatment of Multiple Myeloma.
[3] ClinicalTrials.gov. (n.d.). A Study to Evaluate Daratumumab in Combination With Other Agents for the Treatment of Relapsed or Refractory Multiple Myeloma.
[4] CenterWatch. (n.d.). Darzalex (daratumumab).
[5] DrugPatentWatch.com. (n.d.). Daratumumab (Darzalex) Patent Expiration and Generic Competition.
[6] Express Scripts. (2022). Daratumumab (Darzalex) Average Wholesale Price.